ArticleJournal of thoracic disease2025
Computed tomography-based body composition and systemic inflammation for outcome prediction in patients with resectable esophageal squamous cell carcinoma.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CT-Based assessment of sarcopenia and its association with biologic treatment outcomes in Chinese Children with Crohn's disease.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Computed tomography (CT) can assess a patient's body composition, thereby reflecting an individual's health status. Currently, there is a scarcity of research on the relationship between body composition and prognosis in patients with esophageal squamous cell carcinoma (ESCC) after esophagectomy. We assessed the independent and combined prognostic value of CT-derived body composition parameters, clinical history, pathologic findings, and inflammatory factors in patients with resected ESCC and established a predictive model. Methods: This retrospective analysis included 142 patients with postoperative ESCC. Sarcopenia was diagnosed by assessing the skeletal muscle index at the third lumbar level of CT components. Survival analysis included the Kaplan-Meier method, and the Cox proportional hazards method was employed for multifactor analysis. The consistency index and calibration curve were used to determine the predictive accuracy and discrimination ability of the nomogram. Results: Sarcopenia prevalence among the 142 patients was 62.0% (88/142). The median overall survival (OS) and the 1-, 3-, and 5-year survival rates of patients with sarcopenia were 54.0 months (95% confidence interval: 37.8-70.2), 79.5%, 59.1%, and 44.5%, respectively. Patients without sarcopenia had a median OS of 93.0 months (95% confidence interval: 70.0-116.0), with 1-, 3-, and 5-year survival rates 90.0%, 73.9%, and 65.1%, respectively (P=0.04 for the comparison of OS between the sarcopenia group and the non-sarcopenia group). In the Cox multivariate model, sarcopenia, smoking, lymphocyte albumin score, and tumor-node-metastasis (TNM) stage significantly correlated with postoperative survival in ESCC. The concordance index of the nomogram and calibration curve indicated good agreement between predicted and observed results. Conclusions: Sarcopenia in ESCC was negatively associated with OS. The combination of sarcopenia, pathological parameters, and inflammatory factors could independently predict the survival of patients undergoing ESCC surgery, demonstrating good prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.